USD
+$0.00
(+0.00%
)At Close (As of Oct 16, 2025)
$2.94B
Market Cap
-
P/E Ratio
-0.43
EPS
$29.92
52 Week High
$20.52
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.5B |
Total Revenue | $4.4B |
Cost Of Revenue | $2.8B |
Costof Goods And Services Sold | $2.8B |
Operating Income | $113M |
Selling General And Administrative | $468M |
Research And Development | $112M |
Operating Expenses | $1.4B |
Investment Income Net | - |
Net Interest Income | -$188M |
Interest Income | - |
Interest Expense | $188M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $326M |
Income Before Tax | -$81M |
Income Tax Expense | $80M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$161M |
Comprehensive Income Net Of Tax | - |
Ebit | $107M |
Ebitda | $433M |
Net Income | -$172M |
Field | Value (USD) |
---|---|
Total Assets | $9.6B |
Total Current Assets | $2.5B |
Cash And Cash Equivalents At Carrying Value | $559M |
Cash And Short Term Investments | $559M |
Inventory | $1.1B |
Current Net Receivables | $642M |
Total Non Current Assets | $7.2B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $2.4B |
Intangible Assets Excluding Goodwill | $2.4B |
Goodwill | $3.3B |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $199M |
Other Non Current Assets | - |
Total Liabilities | $5.3B |
Total Current Liabilities | $1B |
Current Accounts Payable | $495M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $4.3B |
Capital Lease Obligations | - |
Long Term Debt | $3.6B |
Current Long Term Debt | $36M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $3.6B |
Other Current Liabilities | $549M |
Other Non Current Liabilities | $499M |
Total Shareholder Equity | $4.3B |
Treasury Stock | - |
Retained Earnings | -$2.3B |
Common Stock | $6.7B |
Common Stock Shares Outstanding | $137M |
Field | Value (USD) |
---|---|
Operating Cashflow | $363M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $326M |
Capital Expenditures | $118M |
Change In Receivables | - |
Change In Inventory | $14M |
Profit Loss | - |
Cashflow From Investment | $79M |
Cashflow From Financing | -$611M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $153M |
Dividend Payout Common Stock | $153M |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$172M |
Field | Value (USD) |
---|---|
Gross Profit | $1.5B |
Total Revenue | $4.4B |
Cost Of Revenue | $2.8B |
Costof Goods And Services Sold | $2.8B |
Operating Income | $113M |
Selling General And Administrative | $468M |
Research And Development | $112M |
Operating Expenses | $1.4B |
Investment Income Net | - |
Net Interest Income | -$188M |
Interest Income | - |
Interest Expense | $188M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $326M |
Income Before Tax | -$81M |
Income Tax Expense | $80M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$161M |
Comprehensive Income Net Of Tax | - |
Ebit | $107M |
Ebitda | $433M |
Net Income | -$172M |
Field | Value |
---|---|
Ex Dividend Date | 2025-08-29 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.29 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Perrigo Company plc is a prominent global player in the self-care sector, renowned for its extensive range of private label over-the-counter pharmaceuticals, dietary supplements, and personal care products. Headquartered in Ireland, the company operates across North America and Europe, where it leverages a strong supply chain and a commitment to high-quality standards to deliver affordable healthcare solutions. With a diversified product portfolio that aligns with current health and wellness trends, Perrigo represents a compelling investment opportunity for institutional investors looking for growth in the dynamic consumer healthcare landscape.